Article Information
History
- June 15, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Tina Schmidt, PhD1,
- Verena Klemis1,§,
- David Schub, PhD1,§,
- Janine Mihm, MD2,
- Franziska Hielscher1,
- Stefanie Marx1,
- Amina Abu-Omar1,
- Sophie Schneitler, MD3,
- Sören L. Becker, MD PhD3,
- Barbara C. Gärtner3,
- Urban Sester, MD2 and
- Martina Sester, PhD1,*
- 1Department of Transplant and Infection Immunology, Saarland University, 66421 Homburg, Germany
- 2Department of Internal Medicine IV, Saarland University, 66421 Homburg, Germany
- 3Institute of Medical Microbiology and Hygiene, Saarland University, 66421 Homburg, Germany
- ↵*Correspondence: Martina Sester, PhD, Saarland University, Department of Transplant and Infection Immunology, Institutes of Infection Medicine, building 47, Kirrberger Straße, D- 66421 Homburg, Germany; email: martina.sester{at}uks.eu
↵§ these authors contributed equally
Posted June 15, 2021.
Immunogenicity and reactogenicity of a heterologous COVID-19 prime-boost vaccination compared with homologous vaccine regimens
